Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Necrosis of uninvolved bone marrow following filgrastim administration in a patient with Burkitt lymphoma undergoing chemotherapy.

Ding L, Rawal A, Luikart S, Wadhwa P.

Br J Haematol. 2012 Oct;159(1):2. doi: 10.1111/bjh.12009. Epub 2012 Aug 9. No abstract available.

PMID:
22881409
3.

Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.

de Wit R, Verweij J, Bontenbal M, Kruit WH, Seynaeve C, Schmitz PI, Stoter G.

J Natl Cancer Inst. 1996 Oct 2;88(19):1393-8.

PMID:
8827017
4.

Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy.

Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM.

J Natl Cancer Inst. 1992 Aug 5;84(15):1201-3. No abstract available.

PMID:
1378905
5.

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.

Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA; Alliance for Clinical Trials In Oncology (ACTION).

Br J Haematol. 2014 Apr;165(1):102-11. doi: 10.1111/bjh.12736. Epub 2014 Jan 15.

6.

[Paradoxical myelosuppression with granulocyte-stimulating factor (G-CSF) and simultaneous administration chemotherapy].

Sanz Ortiz J, Llamazares A, López-Vega JM.

Med Clin (Barc). 1993 Sep 11;101(7):276. Spanish. No abstract available.

PMID:
7538188
7.

A marked increase in myeloblasts in the peripheral blood of a patient with Burkitt lymphoma following granulocyte colony-stimulating factor administration.

Takamatsu H, Yamazaki H, Yamashita T, Takami A, Okumura H, Nakao S.

Acta Haematol. 2008;120(3):174-6. doi: 10.1159/000181184. Epub 2008 Dec 10. No abstract available.

PMID:
19066424
8.

Effects of the in vivo administration of recombinant human granulocyte colony-stimulating factor following cytotoxic chemotherapy on granulocytic precursors in patients with malignant lymphoma.

Ema H, Suda T, Sakamoto S, Tomonaga T, Tsunoda J, Muroi K, Komatsu N, Miwa A, Ohsaka A, Yoshida M, et al.

Jpn J Cancer Res. 1989 Jun;80(6):577-82.

PMID:
2474526
9.

Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.

Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA.

J Natl Cancer Inst. 1997 Mar 5;89(5):395-6. No abstract available.

PMID:
9060963
10.

Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.

Andreola G, Babic A, Rabascio C, Negri M, Martinelli G, Laszlo D.

Eur J Haematol. 2012 Feb;88(2):154-8. doi: 10.1111/j.1600-0609.2011.01719.x. Epub 2011 Nov 17.

PMID:
21992403
11.
12.
14.

Ophthalmoparesis due to Burkitt's lymphoma following cardiac transplantation.

Liu GT, Kay MD, Byrne GE, Glaser JS, Schatz N.

Neurology. 1993 Oct;43(10):2147-9. No abstract available.

PMID:
8413988
15.

Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.

Yoshida O, Kakehi Y, Arai Y, Tomoyoshi T, Okada Y, Matsuda T, Mikami O, Fukuyama T, Hida S, Okabe T.

Int J Urol. 1995 Nov;2(5):316-21. Erratum in: Int J Urol 1996 Jan;3(1):80.

16.

Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer.

Fountzilas G, Skarlos D, Giannakakis T, Athanasiades A, Bafaloukos D, Kalogera-Fountzila A, Bamia C, Pavlidis N, Kosmidis P.

Eur J Cancer. 1994;30A(7):965-9.

PMID:
7524579
17.

Exacerbation of palmoplantar pustulosis by granulocyte colony-stimulating factor.

Kurokawa I, Umehara M, Iwai T, Hamanishi S.

Int J Dermatol. 2005 Jun;44(6):529-30. No abstract available.

PMID:
15941453
18.

Massive chemotherapy with autologous bone marrow transplantation in Burkitt's lymphoma. A review of 50 patients treated in France.

Philip T, Hartmann O, Pinkerton R, Patte C, Biron P, Soulliet G, Bernard JL, Freycon F, Bordigoni P, Laporte JP, et al.

Rev Fr Transfus Immunohematol. 1985 Nov;28(5):521-9. No abstract available.

PMID:
2419957
20.

A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.

Seymour AM, de Campos E, Thatcher N, De Greve J, Cunningham D, Howell A, Tueni E, Bron DG, Steward WP, Berdel WE, et al.

Eur J Cancer. 1995 Dec;31A(13-14):2157-63.

PMID:
8652235

Supplemental Content

Support Center